P1079: Comparison of Novel Salvage Regimens and Traditional Salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma

Ermann, Daniel A.; Vardell, Victoria A.; Zacholski, Erin; Fegley, Amanda; Modi, Dipenkumar; Fedak, Kalub; Sundaram, Suchitra; Rajeeve, Sridevi; Goyal, G.; Hatic, Haris; Torka, Pallawi; Aqeel, Sheeba Ba; Borogovac, Azra; MacDougall, Kira; Kothari, S.; Kress, Anna; Travers, Elizabeth; Chilakamarri, N.; Brém, Elizabeth; Fitzgerald, L.; Wagner, Courtney L.; Hu, Biao; Stephens, D.; Shah, Harsh

doi:10.1097/01.hs9.0000847184.45889.7a

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are significant clinical problems associated with the treatment of recurrent or relapsing cHL, although beneficial in some circumstances, traditional salvage chemotherapy regimens are accompanied by significant toxicity and may not be appropriate for many patients [7]. Pembrolizumab's introduction has created a new path for individuals with refractory illness, promising better outcomes with a good safety profile [7].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Hossain,

Kharel,

Akter

et al. 2023

Cureus

View full text Add to dashboard Cite

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherapy for recurrent and relapsed cHL. We found eight appropriate articles through systematic search and conducted in-depth analysis to find insights into the effectiveness and safety profiles of pembrolizumab by analyzing clinical trial data in patients with recurrent and relapsed cHL. Analysis of the studies shows that response rates, progression-free survival, and patient-reported quality of life have all significantly improved. However, immune-related consequences are among the adverse outcomes. The necessity for continued study is highlighted by the variation in reported adverse events and follow-up times. Clinicians, researchers, and other healthcare professionals can use this study as a resource to provide knowledgeable and individualized patient care in cHL.

show abstract

Section: Introductionmentioning

confidence: 99%